Shanghai Pharmaceuticals Holding Co., Ltd
SHPMYOTCHealthcare● Active
$7.60
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$8.32
52W Low$6.83
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SHPMY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $283.58B | $275.25B | $260.30B | $231.98B | $215.82B |
| Cost of Revenue | $253.16B | $244.62B | $228.97B | $201.49B | $187.28B |
| Gross Profit | $30.42B | $30.63B | $31.33B | $30.49B | $28.54B |
| Gross Margin %(computed) | 10.73% | 11.13% | 12.04% | 13.14% | 13.23% |
| Operating Expenses | |||||
| R&D Expenses | $2.34B | $2.39B | $2.20B | $2.11B | $1.99B |
| G&A Expenses | $5.31B | $1.77B | $1.71B | $1.20B | $1.41B |
| Total Operating Expenses | $20.47B | $22.49B | $23.66B | $21.71B | $20.62B |
| Operating Income | $9.94B | $8.14B | $7.67B | $9.01B | $8.21B |
| Operating Margin %(computed) | 3.51% | 2.96% | 2.95% | 3.89% | 3.80% |
| Interest Income | $0.40B | $0.52B | $0.39B | $0.44B | $0.34B |
| Interest Expense | $1.69B | $1.63B | $1.66B | $1.69B | $1.52B |
| Income Before Tax | $9.82B | $8.02B | $7.05B | $8.81B | $8.14B |
| Income Tax Expense | $2.85B | $2.15B | $1.89B | $1.82B | $1.87B |
| Net Income | $5.72B | $4.55B | $3.77B | $5.62B | $5.09B |
| Net Margin %(computed) | 2.02% | 1.65% | 1.45% | 2.42% | 2.36% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $7.70 | $6.15 | $5.10 | $8.05 | $8.95 |
| Wtd Avg Shares | 0.74B | 0.74B | 0.74B | 0.70B | 0.57B |
| EBITDA | $14.37B | $12.06B | $10.90B | $12.42B | $11.27B |
| EBITDA Margin %(computed) | 5.07% | 4.38% | 4.19% | 5.35% | 5.22% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Shanghai Pharmaceuticals Holding Co., Ltd data
About Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) Income Statement
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SHPMY reported revenue of $283.58B, gross profit of $30.42B (gross margin 10.73%), and net income of $5.72B — a net profit margin of 2.02%.
Frequently asked questions
SHPMY · 4 questionsShanghai Pharmaceuticals Holding Co., Ltd (SHPMY) reported revenue of $283.58B for 2025, up 3.0% year-over-year.
SHPMY revenueSHPMY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09